Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS 9	JUL 27	CA/CAplus enhanced with new citing references
NEWS 10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS 11	JUL 21	USGENE adds bibliographic and sequence information
NEWS 12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS 13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 15	AUG 17	CAS REGISTRY, the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
NEWS 16	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 17	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 18	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:11:07 ON 06 SEP 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 21:11:14 ON 06 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2
DICTIONARY FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s ibandronic
L1 1 IBANDRONIC

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 114084-78-5 REGISTRY
ED Entered STN: 23 Apr 1988
CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI)
OTHER NAMES:
CN BPH 24
CN Ibandronate
CN Ibandronic acid
CN [1-Hydroxy-3-(methylpentylamino)propylidene]diphosphonic acid
MF C9 H23 N O7 P2
CI COM
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
      CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
      IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
      PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
      USPATFULL
        (*File contains numerically searchable property data)
    Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

            723 REFERENCES IN FILE CA (1907 TO DATE)
             29 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            726 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s ibandronic sodium
            1 IBANDRONIC
       344247 SODIUM
L2   0 IBANDRONIC SODIUM
              (IBANDRONIC(W)SODIUM)

=> s 138844-81-2
L3   1 138844-81-2
              (138844-81-2/RN)

=> s 138926-19-9
L4   1 138926-19-9
              (138926-19-9/RN)

=> d l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 138844-81-2 REGISTRY
ED Entered STN: 07 Feb 1992
CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-,
    sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-,
    monosodium salt (9CI)
OTHER NAMES:
CN BM 21.0955
CN BM 21.0955Na
CN Bondronat
CN Bondronate
CN Boniva
CN Bonviva
CN Ibandronate sodium
MF C9 H23 N O7 P2 . Na
CI COM

SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, MRCK*, PROMT, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (114084-78-5)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

87 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
87 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 2
1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d l4 1

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 138926-19-9 REGISTRY
ED Entered STN: 14 Feb 1992
CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt, hydrate (1:1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-, monosodium salt, monohydrate (9CI)
OTHER NAMES:
CN BM 21.0955Na.H2O
CN Ibandronate sodium monohydrate
CN Monosodium ibandronate monohydrate
MF C9 H23 N O7 P2 . H2 O . Na
SR CAS Client Services
LC STN Files: ADISINSIGHT, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, IMSPATENTS, IMSRESEARCH, MRCK*, PATDPASPC, PROUSDDR, PS, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (114084-78-5)



25 REFERENCES IN FILE CA (1907 TO DATE)
25 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.60	24.82

FILE 'CAPLUS' ENTERED AT 21:14:12 ON 06 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 4 Sep 2009 (20090904/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

```
=> s l3 or l4
            87 L3
            25 L4
L5         106 L3 OR L4

=> s amorphous
L6      301133 AMORPHOUS

=> s l5 and l6
L7           5 L5 AND L6

=> d l7 fbib ab hitstr 1-5

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2009:876533  CAPLUS
DN   151:181953
TI   Solid and crystalline ibandronate sodium and processes for preparation
     thereof
IN   Lifshitz-Liron, Revital; Bayer, Thomas; Aronhime, Judith; Pinchasov,
     Michael
PA   Teva Pharmaceutical Industries Ltd., Israel
SO   U.S., 32pp., Cont. of U.S. Ser. No. 410,825. now abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    -------------------      --------
PI   US 7563918           B2    20090721    US 2006-644568           20061222
     US 20070179119       A1    20070802
                                            US 2004-604026P     P    20040823
                                            US 2005-690867P     P    20050616
                                            US 2005-211062      B1   20050823
                                            US 2006-410825      B1   20060424
     DE 202005021414      U1    20080424    DE 2005-202005021414     20050823
                                            US 2004-604026P     P    20040823
                                            US 2005-690867P     P    20050616
                                            EP 2005-791142      A    20050823
     EP 1930011           A2    20080611    EP 2008-2626             20050823
     EP 1930011           A3    20080618
          R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
              IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
                                            US 2004-604026P     P    20040823
                                            US 2005-690867P     P    20050616
                                            EP 2005-791142      A3   20050823

PATENT FAMILY INFORMATION:
FAN  2006:333490
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    -------------------      --------
PI   WO 2006024024        A2    20060302    WO 2005-US30500          20050823
     WO 2006024024        A3    20060629
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
CA	2576659	A1	20060302	CA	2005-2576659		20050823
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823
EP	1713489	A2	20061025	EP	2005-791142		20050823

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823
JP	2007512237	T	20070517	JP	2006-536948		20050823
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823
CN	101022812	A	20070822	CN	2005-80028503		20050823
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823
DE	202005021414	U1	20080424	DE	2005-202005021414		20050823
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				EP	2005-791142	A	20050823
EP	1930011	A2	20080611	EP	2008-2626		20050823
EP	1930011	A3	20080618				

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				EP	2005-791142	A3	20050823
IN	2007DN00555	A	20070817	IN	2007-DN555		20070122
				US	2004-604026P	P	20040823
				WO	2005-US30500	W	20050823
MX	2007002286	A	20080828	MX	2007-2286		20070222
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823
KR	2007043043	A	20070424	KR	2007-705922		20070314
				US	2004-604026P	P	20040823
				US	2005-690867P	P	20050616
				WO	2005-US30500	W	20050823

AB The present invention relates to solid amorphous and crystalline forms of ibandronate sodium. Thus, a solution of NaOH (0.63 g) in water/isopropanol (IPA) was added dropwise to a solution of amorphous ibandronic acid (5 g) in water/IPA at reflux temperature, and the reaction mixture

maintained at reflux temperature for 4 h to obtain a pH of 3.93-4.01. The reaction mixture was then cooled to room temperature, stirred for 72 h, and further cooled using an ice-bath. The precipitate was filtered, washed, and dried in a vacuum oven at 50° to give 4.4 g of ibandronate sodium crystal form F.

IT 138844-81-2P, Ibandronate sodium
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of solid amorphous and crystalline ibandronate sodium)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:724495 CAPLUS
DN 147:125584
TI Novel polymorphic forms of ibandronate for tablets
IN Reddy, Muddasani Pulla; Usharani, Vattikuti; Chowdary, Nannapaneni Venkalah
PA Natco Pharma Limited, India
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007074475	A2	20070705	WO 2006-IN501	20061221
WO 2007074475	A3	20070907		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

IN 2005-CH1936 A 20051227
IN 2005CH01936 A 20070720 IN 2005-CH1936 20051227

AB The present invention relates to novel and stable polymorphic forms of ibandronate monosodium monohydrate and processes for their preparation and pharmaceutical compns. containing them, such as tablets. Ibandronate monosodium monohydrate is useful as bone resorption inhibitor. The novel crystalline forms are designated as Form I, Form II and the amorphous ibandronate monosodium monohydrate as Form III. Thus, the reaction of 100 g of 3-(N-methyl-N-pentylamino)propionic acid-HCl and 49 g of crystalline phosphorous acid at 75°, followed by the addition of phosphorous trichloride and adjusting the pH to 4.3-4.4 using NaOH yielded 145 g of ibandronate. Ibandronate prepared (25 g) was dissolved in 200 mL of water, water was distilled of from the reaction mass and 100 mL of fresh water was added. The reaction mass was treated with 2 g of carbon and filtered. To the filtrate 200 mL of acetone were added at 50-60° resulting in immediate crystallization of ibandronate. The reaction mass was cooled to 25° and maintained for 1 h before filtration. The wet solid was washed with acetone and dried at 60° to get 20 g of Form I crystals of ibandronate monosodium monohydrate. Form I crystals of ibandronate monosodium monohydrate prepared were formulated into tablets containing equivalent
to 150 mg of ibandronic acid per single dosage unit.

IT 138926-19-9P, Ibandronate sodium monohydrate
RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of polymorphic forms of ibandronate monosodium monohydrate for tablets)

RN 138926-19-9 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt, hydrate (1:1:1) (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:333490 CAPLUS

DN 144:338225

TI Preparation of solid and crystalline ibandronate sodium

IN Lifshitz-Liron, Revital; Bayer, Thomas; Aronhime, Judith

PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceutical Usa, Inc.

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024024	A2	20060302	WO 2005-US30500	20050823
	WO 2006024024	A3	20060629		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
	CA 2576659	A1	20060302	CA 2005-2576659	20050823
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				WO 2005-US30500	W 20050823
	EP 1713489	A2	20061025	EP 2005-791142	20050823
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				WO 2005-US30500	W 20050823
	JP 2007512237	T	20070517	JP 2006-536948	20050823
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				WO 2005-US30500	W 20050823
	CN 101022812	A	20070822	CN 2005-80028503	20050823
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				WO 2005-US30500	W 20050823
	DE 202005021414	U1	20080424	DE 2005-202005021414	20050823
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				EP 2005-791142	A 20050823
	EP 1930011	A2	20080611	EP 2008-2626	20050823
	EP 1930011	A3	20080618		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				EP 2005-791142	A3 20050823
	IN 2007DN00555	A	20070817	IN 2007-DN555	20070122
				US 2004-604026P	P 20040823
				WO 2005-US30500	W 20050823
	MX 2007002286	A	20080828	MX 2007-2286	20070222
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616

				WO 2005-US30500	W	20050823
	KR 2007043043	A	20070424	KR 2007-705922		20070314
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				WO 2005-US30500	W	20050823

PATENT FAMILY INFORMATION:

FAN 2009:876533

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 7563918	B2	20090721	US 2006-644568		20061222
	US 20070179119	A1	20070802			
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				US 2005-211062	B1	20050823
				US 2006-410825	B1	20060424
	DE 202005021414	U1	20080424	DE 2005-202005021414		20050823
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				EP 2005-791142	A	20050823
	EP 1930011	A2	20080611	EP 2008-2626		20050823
	EP 1930011	A3	20080618			
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				EP 2005-791142	A3	20050823

AB The present invention relates to solid amorphous and crystalline forms of ibandronate sodium. Thus, ibandronate sodium was dissolved in DMSO and 1-butanol was added to it, and the precipitate was isolated by vacuum filtration, washed with 1-butanol and dried at 50° to obtain ibandronate sodium crystal form C.

IT 138844-81-2P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of solid amorphous and crystalline forms of ibandronate sodium)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:11476 CAPLUS

DN 144:94242
TI Solid and crystalline ibandronic acid
IN Bayer, Thomas; Dolitzky, Ben-Zion; Lifshitz-Liron, Revital; Perutski, Inna; Pinchasov, Michael
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceutical USA, Inc.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2006002348	A2	20060105	WO 2005-US22410		20050623
	WO 2006002348	A3	20060504			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
	CA 2571433	A1	20060105	CA 2005-2571433		20050623
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				WO 2005-US22410	W	20050623
	EP 1687007	A2	20060809	EP 2005-763415		20050623
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				WO 2005-US22410	W	20050623
	US 20070161606	A1	20070712	US 2006-525804		20060922
	US 7511174	B2	20090331			
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				US 2005-165481	B1	20050622
				US 2006-331995	B1	20060112
	IN 2006DN07758	A	20070817	IN 2006-DN7758		20061220
				US 2004-582500P	P	20040623
				WO 2005-US22410	W	20050623
	MX 2007000087	A	20071106	MX 2007-87		20061220
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				WO 2005-US22410	W	20050623
	US 20090023949	A1	20090122	US 2008-218197		20080710

				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				US 2005-165481	B1	20050622
				US 2006-331995	B1	20060112
				US 2006-525804	A3	20060922
	US 20090069598	A1	20090312	US 2008-288025		20081015
				US 2004-582500P	P	20040623
				US 2004-620016P	P	20041018
				US 2005-690868P	P	20050616
				US 2005-165481	B1	20050622
				US 2006-331995	B1	20060112
				US 2006-525804	A3	20060922

AB Provided are novel crystalline and amorphous forms of ibandronic acid, methods for their preparation, and pharmaceutical compns. containing them.

Also provided are methods for purifying and assaying ibandronic acid in any crystalline form (or amorphous). Amorphous ibandronic acid was prepared by drying a solution and a crystal form S1 prepared from the amorphous form by adding acetone to a solution

IT 138844-81-2P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(solid and crystalline ibandronic acid)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



● Na

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:612312 CAPLUS
DN 143:97528
TI An improved process for the preparation of alkyl- and aryl-substituted α-hydroxy-1,1-ethanediphosphonic acids and salts thereof by solvent-free reaction of carboxylic acids with phosphorous acid and phosphorus oxychloride
IN Grassi, Simona; Volante, Anna
PA Lyogen Limited, Cyprus
SO PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063779	A2	20050714	WO 2004-EP14556	20041222
	WO 2005063779	A3	20050929		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				IT 2003-MI2582	A 20031223
				IT 2004-MI80	A 20040122
	IT 2004MI0080	A1	20040422	IT 2004-MI80	20040122
	CA 2551230	A1	20050714	CA 2004-2551230	20041222
				IT 2003-MI2582	A 20031223
				IT 2004-MI80	A 20040122
				WO 2004-EP14556	W 20041222
	EP 1716161	A2	20061102	EP 2004-804152	20041222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
				IT 2003-MI2582	A 20031223
				IT 2004-MI80	A 20040122
				WO 2004-EP14556	W 20041222
	US 20070112197	A1	20070517	US 2006-584022	20061025
				IT 2003-MI2582	A 20031223
				IT 2004-MI80	A 20040122
				WO 2004-EP14556	W 20041222

OS CASREACT 143:97528; MARPAT 143:97528

AB α-Hydroxy-1,1-ethanediphosphonic acids R(CH2)mC(OH)[PO(OH)2]2 [m = 1-8; R = dialkylamino or 5- or 6-membered (hetero)aryl, preferably imidazolyl and pyridinyl], preferably risedronic, zoledronic and ibandronic acids, useful in therapy as inhibitors of bone reabsorption (no data) were prepared by reaction carboxylic acids R(CH2)mCOOH (same m, R) with 2-4 equiv of POCl3 and 8-12 equiv of H3PO3, preferably the carboxylic acid:POCl3:H3PO3 ratio is 1:3:10. In an example, addition of 0.19 mol of POCl3 to a mixture of 0.06 mol of (3-pyridinyl)acetic acid and 0.58 mol of H3PO3 followed by stirring at 60-70° for 24 h with subsequent aqueous work-up gave 1-hydroxy-2-(3-pyridinyl)-1,1-ethanediphosphonic acid (risedronic acid) in 60% yield. Amorphous monosodium salt of 1-hydroxy-2-[(methyl)(pentyl)amino]-1,1-1,1-ethanediphosphonic acid (monosodium ibandronate), useful in the pharmaceutical use due of its increased bioavailability (no data) was prepared by neutralization of 10 g of analogously prepared ibandronic acid in 200 mL of water by 1M NaOH to pH 4.3-4.4 and lyophilization of the resulting solution

IT 138844-81-2DP, amorphous
RL: SPN (Synthetic preparation); PREP (Preparation)
(improved process for preparation of α-hydroxy-1,1-ethanediphosphonic acids by solvent-free phosphonation of carboxylic acids by phosphorous acid and phosphorus oxychloride)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



● Na

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT